



## Paraprost

## Chemical Properties

CAS No. :	8058-79-5
Formula:	C10H21N3O8
Molecular Weight:	311.291
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Paraprost consists of 1-glutamic acid, alanine, and glycine. It was used in prostate hypertrophy drug therapy.
Targets(IC50)	Others,Reductase

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.2124 mL	16.0622 mL	32.1244 mL
5 mM	0.6425 mL	3.2124 mL	6.4249 mL
10 mM	0.3212 mL	1.6062 mL	3.2124 mL
50 mM	0.0642 mL	0.3212 mL	0.6425 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

- Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. WITHDRAWN: Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011 May 11;(5):CD001042. doi: 10.1002/14651858.CD001042.pub2. Review. PubMed PMID: 21563128.
- Okada H. [BPH pharmacotherapy (miscellaneous)]. Nihon Rinsho. 2002 Dec;60 Suppl 11:367-72. Review. Japanese. PubMed PMID: 12599602.
- Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD001042. PubMed PMID: 10796739.
- MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000 May;85(7):836-41. Review. PubMed PMID: 10792162.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481